Healthcare providers, pharmaceutical companies and nonprofit organizations will develop standards to identify shortage risks for seven pre-selected pediatric cancer medications, according to an Oct. 28 news release from the administration.
The goal of the pilot program is to prevent disruptions to patient care and drug distribution for children and families facing cancer, the release said. The End Drug Shortages Alliance will publish a report on the program’s findings in 2025 when the pilot ends.
Healthcare providers participating in the pilot program are Children’s Hospital of Philadelphia, Washington, D.C.-based Children’s National Hospital, Children’s Mercy Kansas City (Mo.), Cincinnati Children’s Hospital Medical Center, Stanford (Calif.) Medicine Children’s Health, Memphis, Tenn.-based St. Jude Children’s Research Hospital and Houston-based Texas Children’s Hospital.
Pharmaceutical companies Cencora and Morris & Dickson, and nonprofit organizations Angels for Change, the Children’s Hospital Association and US Pharmacopeia will also participate.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
